Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing

Cancer Research
Hans K EricksonWalter A Blättler

Abstract

Antibody-drug conjugates are targeted anticancer agents consisting of a cytotoxic drug covalently linked to a monoclonal antibody for tumor antigen-specific activity. Once bound to the target cell-surface antigen, the conjugate must be processed to release an active form of the drug, which can reach its intracellular target. Here, we used both biological and biochemical methods to better define this process for antibody-maytansinoid conjugates. In particular, we examined the metabolic fate in cells of huC242-maytansinoid conjugates containing either a disulfide linker (huC242-SPDB-DM4) or a thioether linker (huC242-SMCC-DM1). Using cell cycle analysis combined with lysosomal inhibitors, we showed that lysosomal processing is required for the activity of antibody-maytansinoid conjugates, irrespective of the linker. We also identified and characterized the released maytansinoid molecules from these conjugates, and measured their rate of release compared with the kinetics of cell cycle arrest. Both conjugates are efficiently degraded in lysosomes to yield metabolites consisting of the intact maytansinoid drug and linker attached to lysine. The lysine adduct is the sole metabolite from the thioether-linked conjugate. However, the l...Continue Reading

References

Dec 1, 1978·Cancer Treatment Reviews·B F Issell, S T Crooke
Jan 1, 1991·Developmental Pharmacology and Therapeutics·G M PacificiA Rane
Jul 15, 1991·Biochemical and Biophysical Research Communications·K OdaK Kato
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E J BowmanK Altendorf
Jan 7, 1972·Nature·C A HomewoodV C Baggaley
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·C LiuR V Chari
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony W TolcherEric K Rowinsky
Apr 5, 2003·Cancer Cell·Gillian Payne
Nov 25, 2003·The Journal of Pharmacology and Experimental Therapeutics·Hongsheng XieWalter A Blättler
Jan 8, 2004·Chemical & Pharmaceutical Bulletin·John M CassadyEckhard Leistner
May 6, 2004·Journal of Cell Science·Anna ZetserNeta Ilan
Aug 10, 2005·Current Opinion in Pharmacology·John M Lambert
Sep 10, 2005·Nature Biotechnology·Anna M Wu, Peter D Senter

❮ Previous
Next ❯

Citations

Jun 29, 2012·Pharmaceutical Research·Kedan Lin, Jay Tibbitts
Jul 11, 2012·Pharmaceutical Research·Gary D Stack, John J Walsh
Aug 21, 2007·Accounts of Chemical Research·Ravi V J Chari
Sep 28, 2013·Bioconjugate Chemistry·Nia S BeckleyHeather L Flores
Apr 27, 2011·Journal of Medicinal Chemistry·Robert Y ZhaoRavi V J Chari
Mar 30, 2007·Nature Clinical Practice. Oncology·Alejandro D Ricart, Anthony W Tolcher
Nov 13, 2012·Nature Medicine·Brian FinanMatthias H Tschöp
Jun 10, 2008·The Cancer Journal·Paul J Carter, Peter D Senter
Oct 13, 2010·Molecular Cancer Therapeutics·Emin OroudjevMary Ann Jordan
Apr 5, 2008·BMC Biotechnology·Hagit BarItai Benhar
Aug 10, 2012·The AAPS Journal·Hans K Erickson, John M Lambert
Jan 5, 2010·Immunotherapy·Zhi-Qiang Huang, Donald J Buchsbaum
Mar 9, 2013·Future Oncology·Parvin F Peddi, Sara A Hurvitz
Jan 22, 2013·Bioanalysis·Surinder KaurMontserrat Carrasco-Triguero
Mar 8, 2013·Future Medicinal Chemistry·Jenny Seligmann, Chris Twelves
Mar 1, 2011·Therapeutic Delivery·Victor S Goldmacher, Yelena V Kovtun
Jun 3, 2014·Breast Cancer Research : BCR·Mark BarokJorma Isola
Jul 24, 2012·Therapeutic Delivery·Saileta PrabhuBert L Lum
Nov 14, 2013·Targeted Oncology·François-Clément Bidard, Olivier Trédan
Jul 16, 2013·Targeted Oncology·Véronique Diéras, Thomas Bachelot
Aug 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Andrea E ProtaMichel O Steinmetz
Feb 28, 2008·Cancer Chemotherapy and Pharmacology·Jordi RodonAnthony W Tolcher
Oct 10, 2012·Annual Review of Medicine·Eric L Sievers, Peter D Senter
Jun 1, 2012·Clinical & Developmental Immunology·Ivetta DanyleskoArnon Nagler
Feb 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hernan CarolRichard B Lock
Oct 17, 2015·International Journal of Molecular Sciences·Feng JiangGe Zhang
May 24, 2011·Expert Opinion on Investigational Drugs·Puja SapraHans-Peter Gerber
Apr 14, 2015·Expert Opinion on Biological Therapy·Tom Van den MooterLuc Dirix
Dec 15, 2015·Expert Opinion on Drug Delivery·Sagun ParakhAndrew M Scott
Mar 24, 2015·Expert Opinion on Drug Discovery·Mahendra P DeonarainJared Marklew
Mar 13, 2013·Expert Opinion on Biological Therapy·Luc Y DirixMarie Dirix
Jan 28, 2015·Drug Delivery·Apostolos PapachristosGregory Sivolapenko
Apr 22, 2011·Expert Opinion on Biological Therapy·Howard A Burris
Dec 15, 2010·Expert Opinion on Investigational Drugs·Andrew G PolsonVanitha Ramakrishnan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.